| abstract |
The present invention relates to T cell receptors (TCRs) that bind to the HLA-A * 02 restriction peptide SLLQHLIGL (SEQ ID NO: 1) derived from the PRAME antigen of germ line cancer. The TCRs of the invention may comprise unnatural mutations in the alpha and / or beta variable domains with respect to a native PRAME TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant diseases. |